Nuveen Asset Management LLC Has $73.17 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nuveen Asset Management LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,530,519 shares of the biopharmaceutical company's stock after selling 8,634 shares during the quarter. Nuveen Asset Management LLC owned 1.20% of Halozyme Therapeutics worth $73,174,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after acquiring an additional 386,618 shares during the period. Snyder Capital Management L P boosted its position in Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after acquiring an additional 105,086 shares during the period. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after acquiring an additional 47,795 shares during the period. Northern Trust Corp raised its stake in shares of Halozyme Therapeutics by 8.7% during the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock worth $87,386,000 after purchasing an additional 145,617 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after purchasing an additional 9,780 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.79 during trading on Friday, reaching $54.54. The company had a trading volume of 1,200,951 shares, compared to its average volume of 1,617,623. The firm's 50 day simple moving average is $59.88 and its two-hundred day simple moving average is $55.86. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company has a market capitalization of $6.72 billion, a PE ratio of 15.90, a PEG ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the business earned $0.79 EPS. The firm's revenue was up 35.2% compared to the same quarter last year. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,697 shares of company stock valued at $1,276,552. Corporate insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.